Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.…
Enovis to Present at the Annual Jefferies Global Healthcare Concerence in London
Enovis (NYSE: ENOV) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 7,802 employees.
The shares were at 25.47 USD on 20 November 2026, down 10.0% over 52 weeks. Its 52-week range is 16.70 USD to 31.67 USD: the price is 19.6% below the high and 52.5% above the low.
Its market capitalisation is 1.47B USD.
Enovis reports return on equity of -79.5%, an operating margin of 4.0% and revenue up 1.8% year over year.
Its debt exceeds its cash by 1.33B USD, a debt-to-equity ratio of 0.93. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 37.83 USD is 48.5% above the current price. The next earnings report is expected on 25 February 2027.